Almost half of U.S. T2D patients (pts) have suboptimal glycemic control (A1c ≥7%). One factor that may be associated with this is clinical inertia related to physician/patient actions or lack of “conformance” to guidelines. We characterized uncontrolled pts in terms of conformance in a large U.S. database (Aetna). This study included T2D pts with at least one A1c ≥7% from Jul 2014-Aug 2015 with ≥6 months pre-index data (Era 1), 12 months post-index data to assess conformance (Era 2), and ≥6 months data post-Era 2 to assess outcomes (Era 3; Figure). Conformance was defined as high (HC) or low (LC) based on provider actions (A1c test performed, T2D office visit, or medication changed/added) and patient goal attainment (A1c <7%). There were 21,171 eligible pts who had the following characteristics: median age 60 years, 55% male, and 80% HC. In a multivariate model, odds ratios (OR) for Era 1 factors associated with HC were: comorbidities (OR=1.09 [1.07, 1.12]), A1c test (OR=1.43 [1.28, 1.60]), PCP visit (OR=3.23 [3.01, 3.47]), nephropathy screening (OR=0.84 [0.79, 0.89]), oral T2D medication use (OR=0.83 [0.77, 0.90]), age (OR=0.99 [0.98, 0.99]), GLP-1 use (OR=1.20 [1.004, 1.44]), and episode risk group score (measure of healthcare utilization; OR=1.01 [1.001, 1.03]).

In conclusion, factors associated with conformance to guidelines, as identified in this study, can help target interventions to improve clinical outcomes in these high risk subgroups.


R. Mehta: None. A. Edwards: None. S. Rajpathak: Employee; Self; Merck & Co., Inc.. A. Sharma: None. K.J. Snow: Employee; Self; Aetna Inc. K. Iglay: Employee; Self; Merck & Co., Inc.. Stock/Shareholder; Self; Merck & Co., Inc..

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at